Tofersen Reaches Its Target: Autopsy Data Confirms ALS Drug Slashes SOD1 Protein by Up to 84%
First human autopsy data confirms tofersen distributes as predicted and reduces toxic SOD1 protein by 45–84% in spinal cord tissue.
Summary
Tofersen is an FDA-approved antisense oligonucleotide drug that silences the mutant SOD1 gene responsible for a hereditary form of ALS. Researchers analyzed autopsy tissue from eight patients who received tofersen during clinical trials, making this the first direct look at how the drug distributes in the human brain and spinal cord. The results were encouraging: drug concentrations matched what animal models had predicted, and SOD1 protein levels in the lumbar spinal cord were reduced by 45 to 84 percent in recently treated patients. Motor neurons showed evidence of successful drug uptake. Some patients displayed immune reactions in the membranes surrounding the spinal cord, though these resolved after treatment ended. The findings validate tofersen's mechanism in living human tissue and support continued development of similar gene-silencing therapies for neurodegenerative diseases.
Detailed Summary
Amyotrophic lateral sclerosis caused by mutations in the SOD1 gene is one of the most devastating and rapidly progressing neurological diseases. Tofersen, approved by the FDA in 2023, works by targeting SOD1 messenger RNA and preventing production of the toxic protein that destroys motor neurons. Until now, direct evidence that the drug reaches its intended targets in the human central nervous system and meaningfully reduces SOD1 had been limited to animal studies and indirect biomarker data from living patients.
This cross-sectional autopsy case series, conducted between 2018 and 2026 at three US academic medical centers, examined tissue from eight deceased SOD1-ALS patients who had received intrathecal tofersen doses ranging from 20 to 100 mg as part of clinical trials or an expanded access program. Tofersen concentrations were measured using hybridization ELISA, while SOD1 mRNA and protein levels were quantified by PCR and ELISA and compared against tofersen-naive SOD1-ALS donor controls.
The key findings are striking. Spinal cord and motor cortex drug concentrations closely matched predictions derived from a preclinical pharmacokinetic model, confirming that animal data translated reliably to humans. In three recently treated donors, lumbar spinal cord SOD1 mRNA and protein reductions ranged from 45 to 84 percent, achieved even though patients had missed one or two scheduled doses before death. Immunohistochemistry confirmed tofersen uptake directly within surviving motor neurons, which also showed markedly reduced SOD1 mRNA. Importantly, misfolded SOD1 protein aggregates were still detected in residual motor neurons of both treated and untreated donors, suggesting incomplete clearance of existing pathological protein.
Five recently treated donors showed meningeal and perivascular lymphocytic immune responses that were absent in donors whose last tofersen dose was more remote, indicating the immune reactions may be treatment-related and transient.
These autopsy findings validate the therapeutic rationale for intrathecal antisense oligonucleotide delivery in ALS and offer a roadmap for similar approaches targeting other neurodegenerative disease genes. Caveats include the very small sample size and the cross-sectional design.
Key Findings
- Lumbar spinal cord SOD1 protein reduced by 45–84% in recently treated patients, even after missing 1–2 doses.
- Drug concentrations in spinal cord and motor cortex matched preclinical pharmacokinetic model predictions.
- Individual motor neurons showed direct tofersen uptake and markedly reduced SOD1 mRNA.
- Misfolded SOD1 protein aggregates persisted in residual motor neurons despite treatment.
- Meningeal immune responses occurred in recently treated patients but resolved after treatment cessation.
Methodology
Cross-sectional autopsy case series of eight SOD1-ALS patients treated with intrathecal tofersen in clinical trials or expanded access, conducted at three US academic centers from 2018–2026. Drug concentrations were measured by hybridization ELISA; SOD1 mRNA and protein reduction was estimated by comparing to a tofersen-naive SOD1-ALS donor cohort using RT-PCR and ELISA. Histological localization used immunohistochemistry and in situ hybridization.
Study Limitations
The sample size of eight donors is very small, limiting statistical power and generalizability. The summary is based on the abstract only, so full methodological details, subgroup analyses, and safety data are unavailable. The cross-sectional design prevents assessment of longitudinal changes in SOD1 reduction over the course of treatment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: